NewsSTAT
Ranked by formulaVerdict: RoutineAfter a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.
Score█████░░░░░5.1
Caveats
- Not randomized: its findings are associations.
VerdictCompetent work. Briefs at most.
Summary from the source
A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ██░░░ 2 | 15% | Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt). |
| Magnitude | ██░░░ 2 | 20% | Solid incremental gain on a meaningful problem. |
| Evidence | ██░░░ 2 | 20% | Limited: single setting, weak baselines, or an observational association presented as causal. |
| Novelty | ██░░░ 2 | 10% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 10% | Some room to improve with obvious engineering. |
| Stakes | ███░░ 3 | 25% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: stakes (major disease, prevention or cure). Red flags: not randomized.
How the score was computed
Score█████░░░░░5.1
- Merit
- 3.8 / 10
- Adjusted merit
- 3.9 / 10
- Attention
- 28%
- Freshness
- 98%